KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Amortization of Deferred Charges: 2009-2021

Historic Amortization of Deferred Charges for Jazz Pharmaceuticals (JAZZ) over the last 7 years, with Mar 2021 value amounting to $15.7 million.

  • Jazz Pharmaceuticals' Amortization of Deferred Charges rose 30.73% to $15.7 million in Q1 2021 from the same period last year, while for Mar 2021 it was $60.3 million, marking a year-over-year increase of 27.68%. This contributed to the annual value of $56.7 million for FY2020, which is 22.12% up from last year.
  • According to the latest figures from Q1 2021, Jazz Pharmaceuticals' Amortization of Deferred Charges is $15.7 million, which was down 2.23% from $16.0 million recorded in Q4 2020.
  • In the past 5 years, Jazz Pharmaceuticals' Amortization of Deferred Charges registered a high of $16.0 million during Q4 2020, and its lowest value of $5.6 million during Q1 2017.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $12.0 million (2020), whereas its average is $13.2 million.
  • Data for Jazz Pharmaceuticals' Amortization of Deferred Charges shows a peak YoY surged of 89.08% (in 2018) over the last 5 years.
  • Jazz Pharmaceuticals' Amortization of Deferred Charges (Quarterly) stood at $10.8 million in 2017, then climbed by 4.62% to $11.3 million in 2018, then climbed by 6.11% to $12.0 million in 2019, then skyrocketed by 33.93% to $16.0 million in 2020, then surged by 30.73% to $15.7 million in 2021.
  • Its Amortization of Deferred Charges was $15.7 million in Q1 2021, compared to $16.0 million in Q4 2020 and $15.8 million in Q3 2020.